• Je něco špatně v tomto záznamu ?

Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair

D. Harnicek, E. Kampmann, K. Lauber, R. Hennel, AS. Cardoso Martins, Y. Guo, C. Belka, S. Mörtl, E. Gallmeier, R. Kanaar, U. Mansmann, T. Hucl, LH. Lindner, W. Hiddemann, RD. Issels,

. 2016 ; 139 (2) : 467-79. [pub] 20160325

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17024144

The tetrahydroisoquinoline trabectedin is a marine compound with approved activity against human soft-tissue sarcoma. It exerts antiproliferative activity mainly by specific binding to the DNA and inducing DNA double-strand breaks (DSB). As homologous recombination repair (HRR)-deficient tumors are more susceptible to trabectedin, hyperthermia-mediated on-demand induction of HRR deficiency represents a novel and promising strategy to boost trabectedin treatment. For the first time, we demonstrate enhancement of trabectedin effectiveness in human sarcoma cell lines by heat and characterize cellular events and molecular mechanisms related to heat-induced effects. Hyperthermic temperatures (41.8 or 43°C) enhanced significantly trabectedin-related clonogenic cell death and G2/M cell cycle arrest followed by cell type-dependent induction of apoptosis or senescence. Heat combination increased accumulation of γH2AX foci as key marker of DSBs. Expression of BRCA2 protein, an integral protein of the HRR machinery, was significantly decreased by heat. Consequently, recruitment of downstream RAD51 to γH2AX-positive repair foci was almost abolished indicating relevant impairment of HRR by heat. Accordingly, enhancement of trabectedin effectiveness was significantly augmented in BRCA2-proficient cells by hyperthermia and alleviated in BRCA2 knockout or siRNA-transfected BRCA2 knockdown cells. In peripheral blood mononuclear cells isolated from sarcoma patients, increased numbers of nuclear γH2AX foci were detected after systemic treatment with trabectedin and hyperthermia of the tumor region. The findings establish BRCA2 degradation by heat as a key factor for a novel treatment strategy that allows targeted chemosensitization to trabectedin and other DNA damaging antitumor drugs by on-demand induction of HRR deficiency.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17024144
003      
CZ-PrNML
005      
20170831120951.0
007      
ta
008      
170720s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ijc.30070 $2 doi
035    __
$a (PubMed)26933761
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Harnicek, Dominique $u Hämatologikum of the Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany.
245    10
$a Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair / $c D. Harnicek, E. Kampmann, K. Lauber, R. Hennel, AS. Cardoso Martins, Y. Guo, C. Belka, S. Mörtl, E. Gallmeier, R. Kanaar, U. Mansmann, T. Hucl, LH. Lindner, W. Hiddemann, RD. Issels,
520    9_
$a The tetrahydroisoquinoline trabectedin is a marine compound with approved activity against human soft-tissue sarcoma. It exerts antiproliferative activity mainly by specific binding to the DNA and inducing DNA double-strand breaks (DSB). As homologous recombination repair (HRR)-deficient tumors are more susceptible to trabectedin, hyperthermia-mediated on-demand induction of HRR deficiency represents a novel and promising strategy to boost trabectedin treatment. For the first time, we demonstrate enhancement of trabectedin effectiveness in human sarcoma cell lines by heat and characterize cellular events and molecular mechanisms related to heat-induced effects. Hyperthermic temperatures (41.8 or 43°C) enhanced significantly trabectedin-related clonogenic cell death and G2/M cell cycle arrest followed by cell type-dependent induction of apoptosis or senescence. Heat combination increased accumulation of γH2AX foci as key marker of DSBs. Expression of BRCA2 protein, an integral protein of the HRR machinery, was significantly decreased by heat. Consequently, recruitment of downstream RAD51 to γH2AX-positive repair foci was almost abolished indicating relevant impairment of HRR by heat. Accordingly, enhancement of trabectedin effectiveness was significantly augmented in BRCA2-proficient cells by hyperthermia and alleviated in BRCA2 knockout or siRNA-transfected BRCA2 knockdown cells. In peripheral blood mononuclear cells isolated from sarcoma patients, increased numbers of nuclear γH2AX foci were detected after systemic treatment with trabectedin and hyperthermia of the tumor region. The findings establish BRCA2 degradation by heat as a key factor for a novel treatment strategy that allows targeted chemosensitization to trabectedin and other DNA damaging antitumor drugs by on-demand induction of HRR deficiency.
650    _2
$a alkylační protinádorové látky $x farmakologie $7 D018906
650    _2
$a apoptóza $x účinky léků $x účinky záření $7 D017209
650    _2
$a protein BRCA2 $x metabolismus $7 D024682
650    _2
$a kaspasy $x metabolismus $7 D020169
650    _2
$a kontrolní body buněčného cyklu $x účinky léků $x účinky záření $7 D059447
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a viabilita buněk $x účinky léků $x účinky záření $7 D002470
650    _2
$a dioxoly $x farmakologie $7 D004149
650    _2
$a chemorezistence $x účinky záření $7 D019008
650    _2
$a histony $x metabolismus $7 D006657
650    _2
$a lidé $7 D006801
650    12
$a indukovaná hypertermie $7 D006979
650    _2
$a biologické modely $7 D008954
650    _2
$a vazba proteinů $7 D011485
650    _2
$a transport proteinů $7 D021381
650    _2
$a proteolýza $x účinky léků $x účinky záření $7 D059748
650    _2
$a rekombinasa Rad51 $x metabolismus $7 D051135
650    _2
$a rekombinační oprava DNA $x účinky léků $x účinky záření $7 D059767
650    _2
$a sarkom $x metabolismus $x patologie $x terapie $7 D012509
650    _2
$a tetrahydroisochinoliny $x farmakologie $7 D044005
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kampmann, Eric $u Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany.
700    1_
$a Lauber, Kirsten $u Department of Radiation Oncology, University Hospital Grosshadern, University of Munich, Munich, Germany.
700    1_
$a Hennel, Roman $u Department of Radiation Oncology, University Hospital Grosshadern, University of Munich, Munich, Germany.
700    1_
$a Cardoso Martins, Ana Sofia $u Hämatologikum of the Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany.
700    1_
$a Guo, Yang $u Department of Medicine II, University Hospital Grosshadern, University of Munich, Munich, Germany.
700    1_
$a Belka, Claus $u Department of Radiation Oncology, University Hospital Grosshadern, University of Munich, Munich, Germany.
700    1_
$a Mörtl, Simone $u Institute of Radiation Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.
700    1_
$a Gallmeier, Eike $u Department of Internal Medicine, Philipps University of Marburg, Marburg, Germany.
700    1_
$a Kanaar, Roland $u Department of Genetics, Cancer Genomics Netherlands, Erasmus Medical Center, Rotterdam, The Netherlands. Department of Radiation Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.
700    1_
$a Mansmann, Ulrich $u Institute of Medical Informatics, Biostatistics, and Epidemiology, Campus Grosshadern, University of Munich, Munich, Germany.
700    1_
$a Hucl, Tomas $u Department of Gastroenterology and Hepatology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Lindner, Lars H $u Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany.
700    1_
$a Hiddemann, Wolfgang $u Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany.
700    1_
$a Issels, Rolf D $u Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany.
773    0_
$w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 139, č. 2 (2016), s. 467-79
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26933761 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170831121542 $b ABA008
999    __
$a ok $b bmc $g 1239825 $s 985057
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 139 $c 2 $d 467-79 $e 20160325 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace